SOCIAL IMPACT

Supporting Healthier Lives Through ESG

While our focus is on making life-changing medicines, we know we also have a responsibility to do our part to address the barriers that stand in the way of people accessing those medicines. It’s part of our dedication to improving lives and creating healthier communities. That effort is woven into who we are as a company. That’s evident when we go beyond medicine to partner with organizations working to improve health equity; when we provide patient support and address affordability barriers; when we invest in sustainable business practices and a diverse workforce to strengthen our future; and when we emphasize the importance of philanthropy throughout our company. In 2022, we made progress towards many of our larger ESG goals that help us have an impact. We’re focused on innovation to move our business forward, and we apply the same forward motion to our efforts to make a difference around the world.
SET NEW ENVIRONMENTAL GOALS IN 2021
for climate, waste and water, including to become carbon neutral in our own operations and purchase all electricity from renewable sources by 2030

REDUCED GREENHOUSE GAS EMISSIONS BY ONE THIRD
from 2012 to 2021, while the overall business has grown

ADDED NEW SOLAR PARKING CANOPY
in Fegersheim, France, capable of producing approximately 4,200 megawatt-hours of electricity per year

ACHIEVED A SCORE OF A- FOR CLIMATE & WATER 2022 CDP SUBMISSIONS
above the biotech and pharmaceutical industry sector average

COMPLETED FULL VALUE-CHAIN EMISSIONS ASSESSMENT
and continually work to identify climate-related risks and opportunities
51 MILLION people around the world reached with Lilly medicines

$7.2 BILLION+ investments in research and development in 2022

$3.7 BILLION+ in donated medicines in 2022¹

$285 MILLION+ committed to global health 2016–2030²

$35 OR LESS PER MONTH for Lilly insulin at the majority of retail pharmacies³

$358 MILLION spent in 2022 with Black business enterprises—150% increase over 2020

~1 MILLION additional people living in low- to middle-income countries expected to get access to quality, affordable insulin through novel collaboration

49% women in management positions, globally⁴

25% minority group members in management positions in the U.S.⁴

 IMPLEMENTED PROPOSAL THAT ALLOWS SHAREHOLDERS TO AMEND THE COMPANY’S BYLAWS

38% BOARD MEMBERS ARE WOMEN⁵

46% BOARD MEMBERS ARE MINORITY GROUP MEMBERS⁵

33% EXECUTIVE COMMITTEE MEMBERS ARE WOMEN⁵

1. Includes value of medicines provided by Lilly to separate charitable organizations that offer free Lilly medicines to qualifying patients. Product donations valued at wholesale acquisition cost, or WAC. 2. Includes financial commitments from Lilly and $13.6 million from the Eli Lilly and Company Foundation, a separate nonprofit organization, commonly referred to as the Lilly Foundation. 3. Terms and conditions apply. At the majority of retail pharmacies. Government restrictions exclude people enrolled in federal government insurance programs from Lilly’s $35 solutions. But federal law provides that Medicare Part D beneficiaries also pay no more than $35 per month for insulin. 4. As of 12/31/2022. 5. As of 3/17/2023.